The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
The conversation discusses creating a topical catalase solution with phosphate buffered saline, glycerin, and polysorbate 20 for hair loss treatment. The user seeks advice on preparing this solution.
Low-level laser therapy (LLLT) is debated for hair regrowth, with some users suggesting it should be combined with treatments like minoxidil and finasteride for effectiveness. Many users express skepticism about LLLT's efficacy and cost, emphasizing the need for the correct wavelength and quality devices.
User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.
The conversation is about purchasing RU58841 for hair loss treatment from Xian Lyphar BioTech. Users confirm the company is legitimate and the price is reasonable.
RU58841, a hair loss treatment, is available on Amazon, but its legitimacy is questioned due to sketchy reviews and lack of lab reports. Some users report seeing results, while others experience negative side effects.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
A new drug, PP405, is being discussed as a potential cure for baldness, with hopes it could be more effective than Minoxidil and Finasteride. Users are skeptical about its effectiveness and the need for lifelong use.
Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.
A 36-year-old has been using oral finasteride (1 mg daily) and topical minoxidil twice a day since September 2023, and added LLLT (helmet) to their routine 2 months ago, seeing positive changes. They also use Ketoconazole shampoo, rotate other medical shampoos, train regularly, eat clean, and manage stress.
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.
A 36-year-old man with androgenetic alopecia suspects copper and zinc deficiencies may be accelerating hair loss and is supplementing copper to address this. He is also monitoring blood sugar levels due to previous prediabetes concerns and plans to test for insulin resistance.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.
The user has been taking 1mg finasteride daily for a year with no improvement in hair loss and reports low cortisol levels, sleep issues, and anxiety changes. The conversation includes discussions on the potential effects of finasteride on cortisol and neurosteroids, with suggestions to consult a doctor and consider other factors.
A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.
Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
A user in Slovakia struggles to get finasteride for hair loss and considers using the UK-based Hair Repair Clinic, which others have used successfully for finasteride and dutasteride. The clinic offers quick service and ships medications directly, but it's unclear if they deliver to Slovakia.
The conversation discusses how to mix pyrilutamide for hair loss treatment, suggesting a mixture of 500mg pyrilutamide with 70% ethanol and 30% propylene glycol, and a potential application dose of 1mL. The user has not personally used pyrilutamide but has researched its preparation and application based on others' experiences.
The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
The user added RU58841 to their finasteride and minoxidil routine, noticing significant improvement in hairline after 52 days. Some users warn about potential side effects of RU58841, while others express curiosity and congratulate the progress.
The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.
RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.
A 45-year-old male successfully slowed hair loss using Nizoral and low-level laser therapy (LLLT) but cannot use Minoxidil, finasteride, or dutasteride for medical reasons. He seeks suggestions for hair regrowth options.